GlassScriptPhysician profile
Erin E Clarke
NPI 1285843599
$7,671.21
in general payments reported to CMS, 2019-2025
28 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $408 · 2021: $431 · 2022: $1,027 · 2023: $1,442 · 2024: $1,555 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,013 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.70 |
| Education | $113.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,475.08 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,337.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,236.64 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $732.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novartis Pharmaceuticals Corporation | $544.87 | 2019-2025 | |
| Genentech USA, INC. | $322.36 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $288.61 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Optinose US, INC. | $258.95 | 2019-2025 | |
| Kaleo, INC. | $208.04 | 2020-2024 | Auvi-Q |
| Pfizer INC. | $199.82 | 2019-2025 | |
| Amgen INC. | $184.22 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $133.36 | 2020-2025 | Gamunex-C, Xembify |
| Ars Pharmaceuticals Operations, INC. | $119.94 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $97.19 | 2020-2023 | |
| Octapharma USA, INC. | $89.85 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $64.09 | 2021-2022 | |
| Shire North American Group INC | $62.84 | 2019 | |
| Csl Behring | $45.52 | 2019 | |
| Pharming Healthcare, INC. | $42.91 | 2021-2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $41.60 | 2019-2022 | |
| Lilly USA, LLC | $40.87 | 2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.67 | 2020 | |
| Galderma Laboratories, L.P. | $25.63 | 2025 | Nemluvio |
| Organon LLC | $24.64 | 2025 | |
| Paratek Pharmaceuticals, INC. | $21.64 | 2025 | Xhance |
| Biocryst US Sales Co., LLC | $15.79 | 2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $12.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.